Evidence map›Paper›PMID 38778266›Full record

ArticleBMC infectious diseases2024

Prevalence of high-risk human papillomavirus genotypes in outpatient Malian women living with HIV: a pilot study.

Ban Traore, Yaya Kassogue, Brehima Diakite, Fousseyni Diarra, Kadidiatou Cisse, Oumar Kassogue, Modibo Diarra, Aissata Coulibaly, Bourama Coulibaly, Hama Diallo and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ban TraoreCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Yaya KassogueCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali. kassoy2@yahoo.fr.
Brehima DiakiteCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Fousseyni DiarraCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Kadidiatou CisseCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Oumar KassogueCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Modibo DiarraCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Aissata CoulibalyCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Bourama CoulibalyCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Hama DialloCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Zoumana DiarraCenter of Listening, Care, Animation, and Counseling for People Living With HIV, Bamako, Mali.
Madani LyCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Aminata MaigaCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Sidi Boula SissokoCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Adama Seydou SissokoCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Cheick Bougadari TraoreCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Bakarou KamateCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Ibrahima TegueteCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Sekou BahCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Guimogo DoloCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Demirkan Besim GurselDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Jane HollDepartment of Neurology, University of Chicago, Chicago, IL, 60637, USA.
Lifang HouInstitute for Global Health, Northwestern University, Chicago, IL, 60611, USA.
Mamoudou MaigaCentre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.

Funding

West Africa Self-Sampling HPV Based Cervical Cancer Control Program (WA-SS-HCCP) for WLWHA: Barriers, challenges, and needsU01CA275129 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI JANE Louise HOLL, Lifang Hou · 2022 to 2026
$3.2M
Infection-Associated Cancer Research Training Program in MaliD43CA260658 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HOU, LIFANG, MAIGA, MAMOUDOU · 2021 to 2025
$1.3M
NCI NIH HHS D43 CA260658NCI NIH HHS U01 CA275129
6 · The paper itself

Abstract

introductionLong-term exposure to high-risk human papillomavirus (Hr-HPV) is a well-known necessary condition for development of cervical cancer. The aim of this study is to screen for Hr-HPV using vaginal self-sampling, which is a more effective approach to improve women's adherence and increase screening rates.

methodsThis pilot study included a total of 100 Women living with HIV (WLWHIV), recruited from the Center for Listening, Care, Animation, and Counseling of People Living with HIV in Bamako. Hr-HPV genotyping was performed on Self-collected samples using the Cepheid GeneXpert instrument.

resultsThe median age of WLWHIV was 44 (interquartile range [IQR], 37-50) years. Approximately 92% of the study participants preferred self-sampling at the clinic, and 90% opted to receive result notifications via mobile phone contact. The overall prevalence of Hr-HPV among study participants was 42.6%, and the most frequent Hr-HPV sub-types observed were HPV18/45 (19.1%), HPV31/35/33/52/58 (13.8%), and HPV39/68/56/66 (12.8%), followed by HPV16 (5.3%), and HPV51/59 (5.3%). WLWHIV under 35 years of age had a higher frequency of Hr-HPV compared to their older counterparts, with rates of 30% versus 11.1% (p = 0.03). The duration of antiretroviral treatment showed an inverse association with Hr-HPV negativity, with patients on treatment for 15 (IQR, 10-18) years versus 12 (IQR = 7-14) years for Hr-HPV positive patients (95% CI [1.2-5.8], t = 3.04, p = 0.003). WLWHIV with baseline CD4 T-Cell counts below 200 exhibited a higher frequency of Hr-HPV compared to those with baseline CD4 T-Cell counts above 200 (17.9% versus 1.9%, p = 0.009). However, other demographics and clinical factors, such as marital status, age of sexual debut, parity, education, history of abortion, history of preeclampsia, and cesarean delivery, did not influence the distribution of Hr-HPV genotypes.

conclusionOur findings indicate that WLWHIV under the age of 35 years old exhibited the highest prevalence of Hr-HPV infection, with HPV18/45 being the most prevalent subtype. Additionally, WLWHIV with baseline CD4 T-Cell counts below 200 showed the highest infection rates.

Indexed as

HIV InfectionsHuman Papillomavirus VirusesPapillomavirus InfectionsAdultFemaleGenotypeHumansMaliMiddle AgedOutpatientsPilot ProjectsPrevalenceGenotypesHr-HPVMaliSelf-samplingWLWHIV

Identifiers

PMID38778266
PMCPMC11110247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.